ClinicalTrials.gov 干细胞登记·· 2 天前AI 评分44
在复发/难治性弥漫大B细胞淋巴瘤患者中测试CAR T细胞疗法后的药物治疗
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
AI 导读
一项II期试验正在测试mosunetuzumab和/或polatuzumab vedotin能否使接受过氟达拉滨联合环磷酰胺化疗及CAR T细胞疗法（tisagenlecleucel、axicabtagene ciloleucel或lisocabtagene maraleucel）后复发或难治的弥漫大B细胞淋巴瘤或IIIb级滤泡性淋巴瘤患者获益。
来源：ClinicalTrials.gov 干细胞登记 · clinicaltrials.gov